Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Om-bitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
- 29 January 2021
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (12), 883-893
- https://doi.org/10.5152/tjg.2020.20696
Abstract
HCV,treatment,direct-acting antiviral,TurkeyKeywords
This publication has 27 references indexed in Scilit:
- Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related CirrhosisGastroenterology, 2017
- Hepatitis C: global epidemiology and strategies for controlClinical Microbiology & Infection, 2016
- Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatmentJournal of Hepatology, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceJournal of Hepatology, 2016
- Chronic hepatitis C: This and the new era of treatmentWorld Journal of Hepatology, 2016
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisThe New England Journal of Medicine, 2015
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP studyClinical Microbiology & Infection, 2015
- Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiencyTurkish Journal of Gastroenterology, 2014
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012